Although E-selectin is recognised as a suitable plasma marker of inflammation and endothelial dysfunction [62], its plasma concentration cannot serve as a marker of atherosclerotic lesions and associated dysfunction in patients with stable and treated CAD. This evidence concerns the gene SELE and endothelial dysfunction.